Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer.

Authors

Jorge R Ledesma, Joshua Nugent, Richard Cheng, Jennifer M Specht, Cecile A Laurent, Janise Roh, Sayan Dasgupta, Allison Meisner, Samir R Thadani, Heather Greenlee, Raymond Liu, Marilyn L Kwan

Published in

JNCI cancer spectrum. Sep 24, 2026. Epub Sep 24, 2026.

Abstract

Adjuvant endocrine therapy (AET) reduces breast cancer (BC) recurrence but may adversely affect cardiometabolic health. We evaluated the association between AET adherence duration and 10-year risk of hypertension, dyslipidemia, diabetes, and mortality among postmenopausal women with early-stage hormone receptor-positive BC.
We conducted a prospective cohort study of 8,365 postmenopausal women with stage I-III hormone receptor-positive BC within Kaiser Permanente Northern California who initiated AET between 2005 and 2013. Adherence (proportion of days covered >80%) was assessed annually using prescription dispensing data. We estimated 10-year cumulative incidence (CI) under six adherence duration strategies (0-5 years) using sequentially doubly robust estimation, adjusting for demographic, clinical, lifestyle, and tumor characteristics. Analyses were stratified by AET type (aromatase inhibitor [AI]; tamoxifen [TAM]).
Overall, 42.7% were adherent for ≥5 years. Compared with nonadherence, 5-year adherence was associated with higher 10-year CI of hypertension (absolute CI difference = 8.81% [95% confidence interval (CI): 4.25-13.4]), dyslipidemia (5.16% [0.31-10.0]), and diabetes (2.58% [0.02-5.14]), but lower all-cause death (10.7% [7.74-13.7]) and BC-specific death (5.37% [3.36-7.38]). Five-year AI adherence was associated with increased hypertension (9.37% [4.54-14.2]), dyslipidemia (6.84% [1.76-11.9]), and diabetes (3.29% [0.58-6.00]), whereas TAM adherence was associated only with hypertension (9.37% [4.54-14.2]). AI adherence was associated with higher dyslipidemia risk than TAM (9.86% [5.09-14.6]).
AI adherence was associated with increased cardiometabolic risk, whereas TAM was associated only with hypertension risk. Despite these risks, AET was associated with improved survival. Further research should evaluate whether cardiometabolic risk factors influence cardiovascular events among BC survivors.

PMID:
42786642
Bibliographic data and abstract were imported from PubMed on 25 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.